Acadian Asset Management
PLX icon

Acadian Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Acadian Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$913K Buy
+331,946
New +$826K ﹤0.01% 1281
2025
Q2 		– Sell
-9,691
Closed -$24K – 1794
2025
Q1 		$24K Buy
+9,691
New +$23.1K ﹤0.01% 1517

Other funds holding PLX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

Acadian Asset Management's PLX Position: Q3 2026 in Review

Acadian Asset Management opened a new position in Protalix BioTherapeutics (PLX) in Q3 2026: 331,946 shares worth $913K. The stake represents ﹤0.01% of the portfolio and ranks #1281 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in PLX as recently as Q1 2025.

Acadian Asset Management first reported a position in PLX in Q1 2025 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Acadian Asset Management held 331,946 shares of Protalix BioTherapeutics worth $913K as of Q3 2026.
  • Protalix BioTherapeutics was a new Acadian Asset Management position in Q3 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2026, its #1281 holding.
  • Acadian Asset Management first reported a position in Protalix BioTherapeutics in Q1 2025 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.